You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Antimicrobial exposure of patients with MC-CRBSI events

From: Surveillance of catheter-related infections: the supplementary role of the microbiology laboratory

Number of antimicrobials a patient had been exposed to % (n = 57)
  None 5.3 (3)
  1 21.1 (12)
  2 33.3 (19)
  3 15.8 (9)
  4 8.8 (5)
  5 7.0 (4)
  6 3.5 (2)
  Unknown 5.3 (3)
Antimicrobial agents, according to class, to which patients were exposed to # % (n = 131 exposure events)
  Carbapenems 29.8 (39)
  Glycopeptides 15.3 (20)
  Polymyxins (colistin) 10.7 (14)
  Antifungals 9.9 (13)
  β-lactamase inhibitors (piperacillin/tazobactam) 6.9 (9)
  Penicillin 4.6 (6)
  Folate pathway inhibitors 3.8 (5)
  Oxazolidnones (linezolid) 3.8 (5)
  Aminoglycosides 3.1 (4)
  Extended-spectrum cephalosporins 3.1 (4)
  Non extended-spectrum cephalosporins 3.1 (4)
  Rifampicin 2.3 (3)
  β-lactamase inhibitors (amoxicillin/clavulanic acid) 1.5 (2)
  Rifafour 0.8 (1)
  Macrolides 0.8 (1)
  Glycylcyclines (tigecycline) 0.8 (1)
  1. #Carbapenems = ertapenem, meropenem and imipenem; glycopeptides = teicoplanin and vancomycin; antifungals = fluconazole, amphotericin B and voriconazole; folate pathway inhibitors = bactrim (sulfamethoxazole and trimethoprim) and dapsone; extended-spectrum cephalosporins = ceftriaxone (rocephin); non extended-spectrum cephalosporins = prophylactic cefazolin (kefzol); macrolides = clarithromycin.